G1 Therapeutics Stock Total Debt
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
G1 Therapeutics fundamentals help investors to digest information that contributes to G1 Therapeutics' financial success or failures. It also enables traders to predict the movement of GTHX Stock. The fundamental analysis module provides a way to measure G1 Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to G1 Therapeutics stock.
GTHX |
G1 Therapeutics Company Total Debt Analysis
G1 Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current G1 Therapeutics Total Debt | 57.17 M |
Most of G1 Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, G1 Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
CompetitionBased on the latest financial disclosure, G1 Therapeutics has a Total Debt of 57.17 M. This is 97.92% lower than that of the Biotechnology sector and 82.4% lower than that of the Health Care industry. The total debt for all United States stocks is 98.92% higher than that of the company.
GTHX Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses G1 Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of G1 Therapeutics could also be used in its relative valuation, which is a method of valuing G1 Therapeutics by comparing valuation metrics of similar companies.G1 Therapeutics is currently under evaluation in total debt category among its peers.
GTHX Fundamentals
| Return On Equity | -1.09 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (0.77) % | |||
| Operating Margin | (0.21) % | |||
| Current Valuation | 364.46 M | |||
| Shares Outstanding | 52.76 M | |||
| Shares Owned By Insiders | 10.92 % | |||
| Shares Owned By Institutions | 54.61 % | |||
| Number Of Shares Shorted | 3.41 M | |||
| Price To Earning | (1.95) X | |||
| Price To Book | 15.34 X | |||
| Price To Sales | 6.48 X | |||
| Revenue | 82.51 M | |||
| Gross Profit | 47.55 M | |||
| EBITDA | (39.01 M) | |||
| Net Income | (47.97 M) | |||
| Cash And Equivalents | 143.96 M | |||
| Cash Per Share | 3.37 X | |||
| Total Debt | 57.17 M | |||
| Debt To Equity | 1.24 % | |||
| Current Ratio | 4.75 X | |||
| Book Value Per Share | 0.47 X | |||
| Cash Flow From Operations | (38.34 M) | |||
| Short Ratio | 1.01 X | |||
| Earnings Per Share | (0.86) X | |||
| Target Price | 7.15 | |||
| Number Of Employees | 100 | |||
| Beta | 1.68 | |||
| Market Capitalization | 377.22 M | |||
| Total Asset | 121.54 M | |||
| Retained Earnings | (779.99 M) | |||
| Working Capital | 85.23 M | |||
| Current Asset | 252.33 M | |||
| Current Liabilities | 9.86 M | |||
| Net Asset | 121.54 M |
About G1 Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze G1 Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of G1 Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of G1 Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |